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THe global burden of posTparTum 
HaemorrHage
Obstetric haemorrhage, especially post-
partum haemorrhage (PPH), was responsible 
for more than a quarter of the estimated 303 
000 maternal deaths that occurred globally in 
2015.1 PPH—commonly defined as a blood 
loss of 500 mL or more within 24 hours after 
birth—affects about 6% of all women giving 
birth.1 Uterine atony is the most common 
cause of PPH, but it can also be caused by 
genital tract trauma, retained placental tissue 
or maternal bleeding disorders. The majority 
of women who experience PPH have no iden-
tifiable risk factor, meaning that PPH preven-
tion programmes rely on universal use of PPH 
prophylaxis for all women in the immediate 
postpartum period. Active management of 
the third stage of labour involves prophylactic 
administration of a uterotonic agent prior to 
delivery of the placenta, as well as delayed 
cord clamping and controlled traction of the 
umbilical cord (in settings where skilled birth 
attendants are available).2 The uterotonic is 
the most important component in terms of 
preventing PPH.3 4 In 2012, WHO recom-
mended oxytocin (10 IU, intravenously or 
intramuscularly) as the uterotonic of choice 
for PPH prevention at birth for all women.5
reCenT innovaTions in ppH prevenTion and 
TreaTmenT researCH
There have been major new developments 
in PPH prevention and treatment in the last 
decade, including technological advance-
ments (such as inhalational oxytocin and 
the non-pneumatic antishock garment), new 
treatment strategies (such as advance distri-
bution of prophylactic misoprostol for self-ad-
ministration after birth, administration of 
oxytocin via Uniiject and care bundles for PPH 
management), as well as large multicountry 
trials of tranexamic acid for PPH treatment 
and a heat-stable formulation of carbetocin 
for PPH prevention.6–12 The increasing 
number of PPH prevention and management 
options makes it challenging for providers 
and health system stakeholders to choose 
where and how to invest limited resources in 
order to optimise health outcomes.
Multiple uterotonics have been eval-
uated for PPH prevention over the past 
four decades, including oxytocin receptor 
agonists (oxytocin and carbetocin), prosta-
glandin analogues (misoprostol, sulprostone, 
carboprost), ergot alkaloids (such as ergo-
metrine/methylergometrine) and combina-
tions of these (oxytocin plus ergometrine, 
or oxytocin plus misoprostol). Trial evidence 
for each of these options has been meta-an-
alysed through multiple separate Cochrane 
systematic reviews that compared one utero-
tonic option against several other options or 
placebo/no treatment. However, subtle but 
important methodological differences have 
emerged between these reviews. For example, 
there are differences in trial eligibility criteria, 
review outcomes and subgroup comparisons. 
Some uterotonic comparisons (eg, oxytocin vs 
misoprostol) appear in more than one review. 
Cochrane review standards have evolved over 
time, meaning more recent reviews may have 
higher methodological rigour.
These problems were largely resolved 
by a recent Cochrane review and network 
meta-analysis (NMA) of 140 trials (88 947 
women) that considered multiple utero-
tonic drug options (single or combination) 
and placebo or no treatment, first published 
in April 2018.13 A single review of multiple 
options meant standardisation of trial eligi-
bility, risk of bias assessment and outcome 
reporting. The NMA also reported on compar-
isons of all options based on the full evidence 
network, providing estimates of effect even 
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Table 1 WHO recommendations on uterotonics for PPH prevention
Context Recommendation
Efficacy and safety of 
uterotonics for PPH prevention
1. The use of an effective uterotonic for the prevention of PPH during the third stage of 
labour is recommended for all births. To effectively prevent PPH, only one of the following 
uterotonics should be used:
 ► Oxytocin (recommendation 1.1).
 ► Carbetocin (recommendation 1.2).
 ► Misoprostol (recommendation 1.3).
 ► Ergometrine/methylergometrine (recommendation 1.4).
 ► Oxytocin and ergometrine fixed dose combination (recommendation 1.5).
1.1 The use of oxytocin (10 IU, IM/IV) is recommended for the prevention of PPH for all births.
1.2 The use of carbetocin (100 µg, IM/IV) is recommended for the prevention of PPH for all 
births in contexts where its cost is comparable to other effective uterotonics.
1.3 The use of misoprostol (either 400 µg or 600 µg, PO) is recommended for the prevention 
of PPH for all births.
1.4 The use of ergometrine/methylergometrine (200 µg, IM/IV) is recommended for the 
prevention of PPH in contexts where hypertensive disorders can be safely excluded prior to 
its use.
1.5 The use of oxytocin and ergometrine fixed-dose combination (5 IU/500 µg, IM) is 
recommended for the prevention of PPH in contexts where hypertensive disorders can be 
safely excluded prior to its use.
1.6 Injectable prostaglandins (carboprost or sulprostone) are not recommended for the 
prevention of PPH.
Choice of uterotonics for PPH 
prevention
2. In settings where multiple uterotonic options are available, oxytocin (10 IU, IM/IV) is the 
recommended uterotonic agent for the prevention of PPH for all births.
3. In settings where oxytocin is unavailable (or its quality cannot be guaranteed), the use of 
other injectable uterotonics (carbetocin, or if appropriate ergometrine/methylergometrine or 
oxytocin and ergometrine fixed-dose combination) or oral misoprostol is recommended for 
the prevention of PPH.
4. In settings where skilled health personnel are not present to administer injectable 
uterotonics, the administration of misoprostol (400 µg or 600 µg PO) by community healthcare 
workers and lay health workers is recommended for the prevention of PPH.
IM, intramuscular; IV, intravenous; PO, per oral; PPH, postpartum haemorrhage.
in the absence of a direct comparison (‘head-to-head’) 
trial. The NMA was closely followed by important new 
findings from a WHO-led, multicountry PPH prevention 
trial in June 2018.11 This trial randomised nearly 30 000 
women in 10 countries to either oxytocin (the recom-
mended standard of care) or a heat-stable formulation 
of carbetocin, and found that heat-stable carbetocin 
was non-inferior to oxytocin for the prevention of PPH 
(defined as blood loss of at least 500 mL), and the use 
of additional uterotonic agents. What should clinicians 
make of these important new findings? It was in this 
context that the Executive Guideline Steering Group on 
Maternal and Perinatal Health advised WHO to prioritise 
the updating of its recommendations on uterotonics for 
PPH prevention.14
updaTed WHo reCommendaTions on uTeroToniCs for 
ppH prevenTion
In December 2018, WHO issued new recommendations 
on uterotonics for PPH prevention (table 1).15 Oxytocin 
(10 IU, intravenously or intramuscularly) remains the 
recommended uterotonic of choice for all births. In 
settings where oxytocin is unavailable (or its quality 
cannot be guaranteed), the use of other injectable utero-
tonics (carbetocin, or if appropriate ergometrine/meth-
ylergometrine or oxytocin and ergometrine fixed-dose 
combination) or oral misoprostol is recommended for 
the prevention of PPH. In those settings where skilled 
health personnel are not present to administer injectable 
uterotonics, the administration of misoprostol (400 µg 
or 600 µg orally) by community healthcare workers and 
lay health workers is recommended for the prevention 
of PPH.
It should be noted that the uterotonic options 
containing ergometrine (ergometrine alone, and 
oxytocin–ergometrine fixed-dose combination) are 
context-specific recommendations, on account of the 
need to exclude the presence of hypertensive disor-
ders prior to its use. This condition may limit their use 
in those settings where there is lack of screening for 
hypertensive disorders in pregnancy. WHO also made a 
context-specific recommendation regarding the use of 
carbetocin for PPH prevention (use carbetocin only in 
contexts where its cost is comparable with other effective 
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uterotonics). While carbetocin is effective in preventing 
PPH (with minimal side effects), it is not available in 
many settings due to its high cost—in the UK, its cost 
is nearly 20 times that of oxytocin.16 The WHO guide-
line panel acknowledged that carbetocin may be cost-ef-
fective in some high-income settings (where the cost of 
managing PPH and its complications is high). However, 
they considered it uncertain whether the additional bene-
fits of carbetocin justify the additional cost of its routine 
implementation at the current unit price—particularly 
in lower—resource settings where effective but cheaper 
alternatives of uterotonics are already available. The use 
of the heat-stable formulation of carbetocin could offer 
cost reductions in avoiding the cold-chain transport and 
storage costs associated with heat-sensitive uterotonics. 
The Guideline Development Group noted that the 
contextual nature of this recommendation may change 
in the future, considering the signed memorandum of 
understanding between WHO and the manufacturer of 
the heat-stable formulation of carbetocin to make this 
option available in public sector facilities of low-income 
and low-middle-income countries at an affordable and 
sustainable price (compared with the United Nations 
Population Fund price of oxytocin).11
The recommendations incorporated several method-
ological advancements compared with previous itera-
tions. The NMA was updated (now contains 196 trials, 
135 559 women) to incorporate latest evidence, including 
the large WHO trial of heat-stable carbetocin.11 13 This 
also required the application of the latest Grading of 
Recommendations Assessments, Development and Eval-
uation (GRADE) Working Group’s guidance on using 
NMA to a WHO guideline development process.17 18 The 
recommendations have placed greater emphasis on a 
woman-centred approach, incorporating findings from a 
qualitative systematic review of women’s perspectives and 
experiences of PPH prevention and treatment.19 This 
evidence proved integral to the panel’s consideration of 
the value women place on outcomes related to blood loss 
after birth, the acceptability and feasibility of different 
uterotonics, and their possible impacts on health equity. 
The recommendations were developed and released 
rapidly (approximately 7 months after the first publica-
tion of the NMA20) through the innovative WHO ‘living 
guideline’ approach to maternal and perinatal health 
recommendations, whereby literature surveillance and 
systematic prioritisation guide the updating of selected 
high-priority recommendations on a continuous basis.14 
This approach has two major advantages—it allows WHO 
to respond much more quickly to important changes 
in the evidence base (ensuring up-to-date guidance is 
always available), and it significantly reduces the time 
and resources required for updating a guideline (by 
focusing efforts only on those individual recommen-
dations where an update is warranted). As uterotonics 
for PPH prevention is an active research area, this new 
approach will allow WHO to respond rapidly as new trial 
evidence continues to emerge. This can in turn translate 
into more rapid improvements in healthcare services and 
health outcomes for women.
adapT THe WHo reCommendaTions To naTional and 
loCal HealTH poliCies and programmes
In light of the updated recommendations, WHO is 
urging international agencies and donors, as well as 
professional associations, clinicians and national health 
systems stakeholders to reassess their national health 
policies and protocols on PPH prevention. Stakeholders 
will need to consider contextual factors (such as the avail-
ability of quality-certified medicines, and the availability 
and training of skilled health personnel) to determine 
which uterotonic option should be used (see figure 1).
CreaTe THe neCessary CondiTions To enCourage 
improvemenTs in CliniCal Care
This is an opportunity to ensure that health facilities 
have copies of updated, evidence-based PPH prevention 
and treatment protocols, job aids and decision-support 
tools available for immediate use in labour, delivery and 
postpartum areas. Any facility where women give birth 
requires access to a functioning supply chain, in order to 
ensure 24/7 availability of uterotonics for PPH preven-
tion, as well as the necessary medicines and equipment 
to provide emergency obstetric care should PPH occur. 
Skilled heath personnel require competency-based 
in-service training, as well as ongoing supportive super-
vision to ensure their PPH prevention and management 
skills are up to date.
Health facilities and clinicians can also take this oppor-
tunity to review their PPH prevention, treatment and case 
fatality reduction targets, and ensure that a data-driven 
approach is being taken to drive improvements in care 
at the time of childbirth. Quality improvement activities 
need to engage all key stakeholders, including clinicians, 
programme management and quality improvement staff. 
Criterion-based audits of clinical records can be used to 
assess the effectiveness of prevention and management of 
PPH at a health facility level.
ensure good-qualiTy uTeroToniCs are available
Oxytocin, ergometrine and the fixed-dose combination 
of oxytocin and ergometrine are heat-sensitive, requiring 
transport and storage at 2°C–8°C. In settings where this 
cannot be guaranteed, the quality and effectiveness of 
these options may be limited.21 Substandard quality miso-
prostol has also been identified in some health facilities.22 
A quality issue affecting one uterotonic may suggest that 
there are quality issues affecting other uterotonic options 
that have been procured, transported or stored under 
similar conditions. It is therefore advised that only qual-
ity-certified uterotonic medicines should be procured. 
While some manufacturer labelling may seem to indicate 
that oxytocin is stable at room temperature, stability may 
not have been tested in the much warmer conditions that 
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Figure 1 Contextual considerations in selecting a uterotonic for postpartum haemorrhage prevention (only quality-assured 
medicines should be used regardless of which uterotonic option is selected). IM, intramuscular; IV, intravenous.
are typical to many low-resource countries, and different 
formulations have different stability characteristics. 
To prevent its degradation and to safeguard its quality, 
oxytocin should always be stored in refrigeration, regard-
less of labelling.
ConClusion
The majority of PPH-related morbidity and mortality are 
preventable through the effective implementation of 
evidence-based guidelines. These new WHO recommen-
dations guide skilled health personnel and other stake-
holders on how best to use uterotonics to prevent PPH 
in women giving birth in facility or community settings 
in high-income, middle-income or low-income countries. 
To implement these recommendations, personnel need 
effective, quality-certified uterotonics, and the neces-
sary training, equipment and support to ensure that all 
women have access to good-quality PPH prevention and 
management care at birth.
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